Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 6/20 | 0.39 |
| ▸ | PPARG | P37231 | 4/20 | 0.38 |
| ▸ | F11 | P03951 | 7/20 | 0.38 |
| ▸ | KLKB1 | P03952 | 5/20 | 0.38 |
| ▸ | PTGDR2 | Q9Y5Y4 | 2/20 | 0.35 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.35 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.34 |
| ▸ | KMO | O15229 | 1/20 | 0.34 |
| ▸ | KLK1 | P06870 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21057015 | 1.00 | PPARA (0.39) | PPARAPPARGF11KLKB1PTGDR2 | |
| SCHEMBL21056978 | 0.87 | PTGDR2 (0.32) | PPARAPTGDR2PTGDRKMO | |
| SCHEMBL21056981 | 0.87 | PTGDR2 (0.32) | PPARAPTGDR2PTGDRKMO | |
| SCHEMBL21057016 | 0.84 | PPARA (0.42) | PPARAPPARGF11KLKB1PTGDR2 | |
| SCHEMBL21057018 | 0.84 | PPARA (0.42) | PPARAPPARGF11KLKB1PTGDR2 | |
| SCHEMBL21056992 | 0.84 | PPARA (0.44) | PPARAPPARGF11KLKB1PTGDR2 | |
| SCHEMBL21056990 | 0.84 | PPARA (0.44) | PPARAPPARGF11KLKB1PTGDR2 | |
| SCHEMBL21056987 | 0.83 | PTGDR2 (0.33) | PPARAPTGDR2PTGDR | |
| SCHEMBL21056984 | 0.83 | PTGDR2 (0.33) | PPARAPTGDR2PTGDR | |
| SCHEMBL31758941 | 0.83 | PPARA (0.40) | PPARAPPARGF11KLKB1SCN9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12221425-B2 | Process for the preparation of CIC-1 chloride channel inhibitors | NMD PHARMA A/S (DK) | 2025-02-11 | — | — | US | claimed |
| EP-3986878-B1 | PROCESS FOR THE PREPARATION OF CLC-1 CHLORIDE CHANNEL INHIBITORS | NMD PHARMA AS (DK) | 2024-09-25 | — | — | EP | claimed |
| CN-111712489-B | Compounds for the treatment of neuromuscular disorders | NMD制药股份公司 | 2023-11-07 | — | — | CN | claimed |
| US-20220298124-A1 | PROCESS FOR THE PREPARATION OF CLC-1 CHLORIDE CHANNEL INHIBITORS | NMD PHARMA A/S (DK) | 2022-09-22 | — | — | US | claimed |
| EP-3986878-A1 | PROCESS FOR THE PREPARATION OF CLC-1 CHLORIDE CHANNEL INHIBITORS | NMD Pharma A/S (DK) | 2022-04-27 | — | — | EP | claimed |
| CN-113993852-A | Process for preparing ClC-1 chloride channel inhibitors | NMD制药股份公司 | 2022-01-28 | — | — | CN | claimed |
| EP-3724173-B1 | COMPOUNDS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS | NMD PHARMA AS (DK) | 2021-09-22 | — | — | EP | claimed |
| WO-2020254554-A1 | PROCESS FOR THE PREPARATION OF CLC-1 CHLORIDE CHANNEL INHIBITORS | NMD PHARMA A/S (DK) | 2020-12-24 | — | — | WO | claimed |
| EP-3724173-A1 | COMPOUNDS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS | NMD Pharma A/S (DK) | 2020-10-21 | — | — | EP | claimed |
| CN-111712489-A | Compounds for the treatment of neuromuscular disorders | NMD制药股份公司 | 2020-09-25 | — | — | CN | claimed |
| WO-2019115781-A1 | COMPOUNDS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS | NMD PHARMA A/S (DK) | 2019-06-20 | — | — | WO | claimed |
| US-20190183863-A1 | Compounds For The Treatment Of Neuromuscular Disorders | NMD PHARMA A/S (DK) | 2019-06-20 | — | — | US | claimed |
| US-12440477-B2 | Compounds for the treatment of neuromuscular disorders | NMD PHARMA A/S (DK) | 2025-10-14 | — | — | US | disclosed |
| US-12221425-B2 | Process for the preparation of CIC-1 chloride channel inhibitors | NMD PHARMA A/S (DK) | 2025-02-11 | — | — | US | disclosed |
| EP-3986878-B1 | PROCESS FOR THE PREPARATION OF CLC-1 CHLORIDE CHANNEL INHIBITORS | NMD PHARMA AS (DK) | 2024-09-25 | — | — | EP | disclosed |
| CN-111712489-B | Compounds for the treatment of neuromuscular disorders | NMD制药股份公司 | 2023-11-07 | — | — | CN | disclosed |
| EP-3724173-A1 | COMPOUNDS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS | NMD Pharma A/S (DK) | 2020-10-21 | — | — | EP | disclosed |
| CN-111712489-A | Compounds for the treatment of neuromuscular disorders | NMD制药股份公司 | 2020-09-25 | — | — | CN | disclosed |
| WO-2019115781-A1 | COMPOUNDS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS | NMD PHARMA A/S (DK) | 2019-06-20 | — | — | WO | disclosed |
| US-20190183863-A1 | Compounds For The Treatment Of Neuromuscular Disorders | NMD PHARMA A/S (DK) | 2019-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12440477-B2 | Compounds for the treatment of neuromuscular disorders | RYR1, CACNB1, RYR2 | PPARA 3247/4885PPARG 3332/4885F11 1805/4885 |
| US-20190183863-A1 | Compounds For The Treatment Of Neuromuscular Disorders | RYR1, CACNB1, RYR2 | PPARA 3247/4885PPARG 3332/4885F11 1805/4885 |
| US-20220298124-A1 | PROCESS FOR THE PREPARATION OF CLC-1 CHLORIDE CHANNEL INHIBITORS | CLIC1, CLCN2, CLIC4 | PPARA 4683/4885PPARG 4814/4885F11 1210/4885 |
| US-12221425-B2 | Process for the preparation of CIC-1 chloride channel inhibitors | CLIC1, CACNA1D, CLIC4 | PPARA 4668/4885PPARG 4834/4885F11 1057/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.